Condition: Eye Cancer · Primary Cancer · Sponsor: Aura Biosciences
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
This description comes directly from the study's public registry record.
Medical Monitor · 617-500-8864 · clinical@aurabiosciences.com
Always discuss trial participation with your own doctor first.
| Byers Eye Institute at Stanford University | Palo Alto, California, United States | Recruiting |
| Bascom Palmer Eye Institute | Miami, Florida, United States | Recruiting |
| Massachusetts Eye and Ear | Boston, Massachusetts, United States | Recruiting |
| Kellogg Eye Center | Ann Arbor, Michigan, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Not Yet Recruiting |
| Cleveland Clinic, Cole Eye Institute | Cleveland, Ohio, United States | Not Yet Recruiting |
| Shields and Shields, PC | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
| Tennessee Retina, PC | Nashville, Tennessee, United States | Recruiting |
| Retina Consultants of Texas | Bellaire, Texas, United States | Recruiting |
| University of Washington | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06643884